Janus Henderson's $223B Portfolio Churned 134 Positions in Q4 2025: Inside the Biotech Pivot
Janus Henderson (WhaleScore 75.50) opened 67 new positions while exiting 67 in Q4 2025 — a 13.4% turnover rate signaling active repositioning. New biotech/med-device bets (ISRG, GPCR, PTGX) hint at a healthcare conviction thesis.
Janus Henderson Group PLC filed its Q4 2025 13F reporting $223.31B in assets under management across 4,350 holdings — and beneath that steady +2.0% QoQ growth lies a portfolio in active transformation. The firm opened 67 brand-new positions while simultaneously exiting 67 others, a 13.4% turnover rate that's unusually high for a $200B+ asset manager. The new entries cluster around biotech and medical devices, suggesting a deliberate healthcare conviction thesis rather than routine rebalancing.
TL;DR — Key Takeaways
- AUM: $223.31B (+2.0% QoQ from $210.77B), WhaleScore 75.50
- Total holdings: 4,350 positions across the consolidated portfolio
- Position churn: 67 new entries + 67 exits = 134 position changes in one quarter
- Top holding: NVIDIA (NVDA) at $15.39B (7.16% of portfolio)
- Biggest new bet: Intuitive Surgical (ISRG) — $897M entry signals surgical robotics conviction
- Biotech cluster: GPCR ($354M) and PTGX ($231M) new positions point to drug discovery expansion
- Largest scale-up: Netflix (NFLX) shares surged +924% — from minor position to meaningful bet
- Profit-taking: Meta (META) trimmed -22%, ADSK cut -89%
- Notable exits: AKRO ($298M), ADP ($263M), GDDY ($166M) — fully liquidated
Filing Snapshot — Q4 2025
| Metric | Q3 2025 | Q4 2025 | Change |
|---|---|---|---|
| Total AUM (13F) | $219.04B | $223.31B | +1.9% |
| Holdings Value Sum | $210.77B | $215.07B | +2.0% |
| Total Positions | 4,336 | 4,350 | +14 |
| New Positions | — | 67 | — |
| Exited Positions | — | 67 | — |
| WhaleScore | — | 75.50 | — |
The WhaleScore of 75.50 places Janus Henderson among the highest-scoring mega-filers — a metric that reflects portfolio concentration, conviction sizing, and active management signals. This isn't a passive indexer; it's a firm making deliberate bets.
Top Holdings — The $67B Mega-Cap Core
Janus Henderson Top Holdings — Q4 2025 ($M)
The top eight positions account for roughly $67B — about 31% of the portfolio. NVIDIA (NVDA) dominates at $15.39B (7.16%), held roughly flat quarter-over-quarter at 82.83M shares. Microsoft (MSFT) sits second at $12.91B (6.00%), though it saw an -8% share reduction — a subtle trim rather than a conviction loss.
Amazon (AMZN) ($7.80B, 3.63%), Alphabet (GOOG) ($7.69B, 3.58%), and Apple (AAPL) ($7.40B, 3.44%) round out the mega-cap core — all held roughly flat. The stability at the top contrasts sharply with the churn happening in the portfolio's middle and tail.
The most actionable signal in the top holdings is META's -22% share reduction — from approximately 7.86M to 6.13M shares. At $4.04B, it remains a significant position, but trimming over a fifth of shares while maintaining every other mega-cap holding suggests Janus Henderson viewed META's late-2024 rally as a profit-taking opportunity.
The 67-Position Churn: Active Repositioning, Not Drift
Opening 67 new positions and exiting 67 in a single quarter is striking for a manager of this scale. For context, this 13.4% position turnover rate far exceeds what you'd see from a passive or index-hugging strategy. Let's break down the most significant moves.
New Positions — The Healthcare Conviction Play
| Ticker | Company | Value | Sector Signal |
|---|---|---|---|
| ISRG | Intuitive Surgical | $897M | Surgical robotics / med-device |
| GPCR | Structure Therapeutics | $354M | GPCR-targeted drug discovery |
| PTGX | Protagonist Therapeutics | $231M | Peptide-based therapeutics |
The ISRG entry at nearly $900M is the headline — that's not a toe-dip, it's an immediate top-50 position. Intuitive Surgical's da Vinci robotic surgical systems represent one of the widest moats in medical technology. Pairing it with GPCR and PTGX — both smaller biotech names in the drug discovery space — suggests a deliberate thesis around healthcare innovation rather than a single opportunistic trade.
Exits — What They're Walking Away From
| Ticker | Company | Exit Value | Read |
|---|---|---|---|
| AKRO | Akero Therapeutics | $298M | Exited another biotech — possible thesis rotation |
| ADP | Automatic Data Processing | $263M | Dropped a defensive payroll compounder |
| GDDY | GoDaddy | $166M | Exited mid-cap internet services |
The AKRO exit is particularly interesting when read alongside the GPCR and PTGX entries. Janus Henderson isn't abandoning biotech — it's rotating within it. Exiting one clinical-stage name while entering two others at a combined $585M suggests the healthcare team made a deliberate swap based on pipeline conviction.
Dramatic Scale-Ups: NFLX +924%, CP +586%
Beyond new positions, several existing holdings saw massive share accumulation:
- Netflix (NFLX) — +924% shares: This transforms NFLX from a token position into a meaningful portfolio bet. The ad-tier monetization thesis continues to attract institutional capital.
- CP (Canadian Pacific Kansas City) — +586% shares: A massive rail infrastructure play, possibly reflecting conviction in cross-border freight demand following the CP-Kansas City Southern merger.
- GKOS (Glaukos) — +183% shares: Another medical device name — ophthalmic surgical devices — reinforcing the healthcare hardware theme.
The GKOS scale-up is easy to overlook but significant: combined with the ISRG entry, Janus Henderson now has multiple large positions in surgical/medical device companies. This isn't a one-off; it's a sector allocation shift.
Profit-Taking: META -22%, ADSK -89%
While most mega-cap holdings were maintained, two notable positions were aggressively trimmed:
- META (-22% shares): Reduced from ~7.86M to 6.13M shares. Still a $4.04B position at 1.88% weight, but this is the most decisive trim among the top holdings. After META's 2024 rally, Janus Henderson chose to take chips off the table.
- ADSK (-89% shares): Autodesk was nearly eliminated. An -89% share reduction is functionally an exit in slow motion — the remaining position is negligible relative to the portfolio.
The META trim alongside the biotech entries tells a coherent story: rotating capital from 2024's winners into 2025's conviction bets.
AUM Trajectory: Steady Climb to $223B
Janus Henderson AUM History (2024–2025)
Janus Henderson's AUM trajectory shows consistent growth from $183.33B in Q1 2024 to $223.31B in Q4 2025 — a 21.8% increase over eight quarters. The only notable drawdown was Q1 2025 (-7.3%), which coincided with broader market weakness. The rebound since has been steady: +11.8% in Q2, +7.4% in Q3, and +1.9% in Q4.
The deceleration to +1.9% QoQ in Q4 doesn't signal weakness — it reflects a $223B portfolio where single-digit growth still represents $4B+ in value creation. The holdings count has stabilized around 4,300-4,350, suggesting the portfolio construction has reached a mature structure.
What Analysts Might Misread
The +2.0% QoQ growth looks boring — the 134-position churn is not. A surface-level read of this filing would focus on the modest AoQ growth and stable top holdings. But beneath that, 67 entries and 67 exits represent an unusually active quarter. The portfolio's top-line stability masks aggressive repositioning in the mid-cap and biotech segments. This is a fund that's maintaining its mega-cap core while completely retooling its growth allocation.
Frequently Asked Questions
What did Janus Henderson buy in Q4 2025?
Janus Henderson opened 67 new positions in Q4 2025. The largest entries were Intuitive Surgical (ISRG) at $897M, Structure Therapeutics (GPCR) at $354M, and Protagonist Therapeutics (PTGX) at $231M. The firm also dramatically scaled up existing positions in Netflix (NFLX) (+924% shares) and Canadian Pacific (+586% shares).
How big is Janus Henderson's portfolio?
Janus Henderson Group PLC reported $223.31B in 13F assets under management as of Q4 2025, up +2.0% from $210.77B in Q3 2025. The portfolio spans 4,350 individual positions.
What is Janus Henderson's largest holding?
NVIDIA (NVDA) is Janus Henderson's largest holding at $15.39B, representing 7.16% of the total portfolio. Microsoft (MSFT) is second at $12.91B (6.00%).
Did Janus Henderson sell any major positions in Q4 2025?
Yes. Janus Henderson exited 67 positions entirely, including Akero Therapeutics ($298M), Automatic Data Processing ($263M), and GoDaddy ($166M). It also aggressively trimmed Meta (META) by -22% of shares and Autodesk (ADSK) by -89%.
What is Janus Henderson's WhaleScore?
Janus Henderson has a WhaleScore of 75.50, which places it among the highest-scoring mega-filers. WhaleScore reflects portfolio concentration, conviction sizing, and active management signals — a high score indicates the fund is making deliberate, concentrated bets rather than passive index tracking.
Related Research
Explore all researchIMC-Chicago filed a $275.42B Q4 2025 13F showing 84 new positions, 84 exits, and a book dominated by ETF, index, and derivative-style exposures.
Mar 29, 2026
Scotiabank's $131.31B investment arm entered 114 new positions in Q4 2025 while trimming its dominant internal fund by 25% — one of the most aggressive quarterly reshuffles among top-100 filers.
Mar 30, 2026
Arrowstreet Capital's systematic models triggered one of Q4 2025's most aggressive Apple trims (-38% shares) while more than doubling Google. With 93 new positions and $170.74B in 13F assets, here's what the quant signals are saying.
Mar 30, 2026
The 220-year-old London-based asset manager's US equity book reveals a distinctly European conviction — GOOGL as the #3 holding at 6.03%, plus aggressive adds in TEVA (+261%), CX (+406%), and new global commodity ETF positions.
Mar 30, 2026
CalPERS' latest 13F reveals $174.90B in reported AUM with VOO at 11.89% — nearly $20B in one S&P 500 ETF. Combined with NVDA at 8.55%, the top-2 holdings account for 20.44% of this pension giant's portfolio.
Mar 30, 2026